A clinical trial update dated August 13, 2026 concerns somatostatin receptor targeted research. The study, registered as NCT04665739, is titled "Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors." This is a Phase 2 trial. Its current status is listed as recruiting. The trial focuses on patients whose bronchial neuroendocrine tumors are somatostatin receptor positive, a characteristic relevant to the therapy under evaluation. No results have been posted for this trial as of the date given. The study status reflects only that participant enrollment is ongoing, not any outcome or efficacy signal. Somatostatin itself remains classified as an unapproved compound used in research contexts. Details on trial design, eligibility, and further updates can be found through the official listing referenced for this study. For general background on somatostatin, readers can consult the compound overview.
Trial Update: Lutetium Lu 177 Dotatate Study in Bronchial NETs Recruiting
See the full somatostatin overview
Source: https://clinicaltrials.gov/study/NCT04665739